MSD's PD-1 inhibitor Keytruda has ruled the immunotherapy of non-small cell lung cancer (NSCLC) for many years, but a bispecific antibody from Summit Therapeutics and partner Akeso looks li
MSD and Daiichi Sankyo have revealed some of the clinical data that prompted them to start pivotal testing of ifinatamab deruxtecan (I-DXd) in patients with previously treated, extensive-st
GSK's severe asthma therapy Nucala could find a new lease of life as a treatment for chronic obstructive pulmonary disease (COPD) after showing a clear benefit in a phase 3 trial.<
Our round-up of financings in the biotech sector this week is led by BioAge Lab's filing of an initial public offering (IPO), with a placeholder target of $100 million, plus sizeable privat
In its second R&D alliance this week, Eli Lilly has formed a partnership with Genetic Leap, a startup that focuses on applying artificial intelligence to the discovery of RNA-targeted t
The fallout from the FDA's recent decision not to approve Lykos Therapeutics' psychedelic treatment has spread to its senior management, with chief executive Amy Emerson stepping down.